Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

J Clin Oncol · 2026 · PMC12794700 · PMID 41385757

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

at the threshold of significanceno p-value reported

However, the corresponding P value of .23 is at the threshold of significance by design, and therefore, it is believed that this result represents a clinically meaningful signal.

also in 43 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.